New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1

Journal of Virology

Volumn 79, Issue 10, 2005, Pages 6291-6298

  Taylor, Deborah R ^a,b   Puig, Montserrat ^a   Darnell, Miriam E R ^a   Mihalik, Kathleen ^a   Feinstone, Stephen M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; DOUBLE STRANDED RNA; INOSINE; INTERFERON; PROTEIN KINASE; SMALL INHIBITORY RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE EXPRESSION; GENE INDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA EDITING; RNA TRANSLATION; VIRUS REPLICATION;

ADENOSINE; CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C; HUMANS; INOSINE; INTERFERON-ALPHA; REPLICON; RNA EDITING; RNA, VIRAL; VIRUS REPLICATION;

ADENOVIRIDAE; HEPATITIS C VIRUS;

EID: 18144401994     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.10.6291-6298.2005     Document Type: Article

References (26)

1. Bass, B. L. 1997. RNA editing and hypermutation by adenosine deamination. Trends Biochem. Sci. 22:157-162.
2. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
3. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
4. Donze, O., R. Jagus, A. E. Koromilas, J. W. Hershey, and N. Sonenberg. 1995. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 14:3828-3834.
5. Foy, E., K. Li, C. Wang, R. Sumpter, Jr., M. Ikeda, S. M. Lemon, and M. J. Gale. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
6. Gale, M. J., M. J. Korth, N. M. Tang, S.-L. Tan, D. A. Hopkins, T. E. Dever, S. J. Polyak, D. R. Gretch, and M. G. Katze. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
7. Gunnery, S., and M. B. Mathews. 1995. Functional mRNA can be generated by RNA polymerase III. Mol. Cell. Biol. 15:3597-3607.
8. Jayan, G. C., and J. L. Casey. 2002. Inhibition of hepatitis delta virus RNA editing by short inhibitory RNA-mediated knockdown of ADAR1 but not ADAR2 expression. J. Virol. 76:12399-12404.
9. Koev, G., R. F. Duncan, and M. M. C. Lai. 2002. Hepatitis C virus IRES-dependent translation is insensitive to an eIF2α-independent mechanism of inhibition by interferon in hepatocyte cell lines. Virology 297:195-202.
10. Lei, M., Y. Liu, and C. E. Samuel. 1998. Adenovirus VAI RNA antagonizes the RNA-editing activity of the ADAR adenosine deaminase. Virology 245:188-196.
11. Lohmann, V., F. Korner, J.-O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
12. Maran, A., and M. B. Mathews. 1988. Characterization of the dsRNA implicated in the inhibition of protein synthesis in cells infected with a mutant adenovirus defective for VA RNAI. Virology 164:106-113.
13. McHutchison, J. G., S. C. Gordon, and E. R. Schiff. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
14. 1. Cell 44:391-400.
15. Polson, A. G., B. L. Bass, and J. L. Casey. 1996. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 380:454-456.
16. Puig, M., M. E. Major, K. Mihalik, and S. M. Feinstone. 2004. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22:991-1000.
17. Saunders, L. R., and G. N. Barber. 2003. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 17:961-983.
18. Scadden, A. D. J., and C. W. J. Smith. 1997. A ribonuclease specific for inosine-containing RNA: a potential role in antiviral defense? EMBO J. 16:2140-2149.
19. Scadden, A. D. J., and C. W. J. Smith. 2001. Specific cleavage of hyper-edited dsRNAs. EMBO J. 20:4243-4252.
20. Taylor, D. R., S. T. Shi, P. R. Romano, G. N. Barber, and M. M. C. Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110.
21. Taylor, D. R. 2000. Hepatitis C virus: evasion of the interferon-induced antiviral response. J. Mol. Med. 78:182-190.
22. Taylor, D. R., B. Tian, P. R. Romano, A. G. Hinnebusch, M. M. C. Lai, and M. B. Mathews. 2001. HCV E2 envelope protein does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. J. Virol. 75:1265-1273.
23. Vyas, J., A. Elia, and M. J. Clemens. 2003. Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA. RNA 9:858-870.
24. Wang, Q., J. Khillan, P. Gadue, and K. Nishikura. 2000. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 290:1765-1768.
25. Wong, S. K., and D. W. Lazinski. 2002. Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proc. Natl. Acad. Sci. USA 99:15118-15123.
26. Wong, S. K., S. Sato, and D. W. Lazinski. 2003. Elevated activity of the large form of ADAR1 in vivo: very efficient RNA editing occurs in the cytoplasm. RNA 9:586-598.